Top U.S. Defense Stocks to Watch According to Jefferies Analysis
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a prominent player in the pharmaceutical industry with a market capitalization of $748 billion, will present the primary overall survival analysis from its Phase 3 monarchE study of Verzenio (abemaciclib) in high-risk early breast cancer at the upcoming European Society for Medical Oncology (ESMO) Annual Meeting in Berlin. According to InvestingPro analysis, Lilly maintains a "GREAT" financial health score, positioning it strongly for continued research and development initiatives.
The late-breaking oral presentation, scheduled for Friday, October 17, will reveal the landmark seven-year analysis of Verzenio in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high-risk early breast cancer. The company’s robust 36.8% revenue growth over the last twelve months reflects its strong market position in oncology treatments.
In addition to the Verzenio data, Lilly will showcase results from several investigational therapies in its oncology pipeline, including olomorasib for KRAS G12C-mutant lung cancer with brain metastases, LY4064809 for PIK3CA-mutant advanced breast cancer, vepugratinib for FGFR3-altered urothelial cancer, and LY4170156 for folate receptor alpha-positive ovarian cancer.
"These data reflect the meaningful progress we have made in strengthening our oncology portfolio," said Jacob Van Naarden, executive vice president and president of Lilly Oncology, in a press release statement.
The ESMO Annual Meeting will take place October 17-21, 2025, with Lilly’s presentations spanning breast, lung, bladder, and ovarian cancers. The company’s focus on targeted therapies highlights its strategy to address specific genetic mutations and molecular targets across multiple tumor types.
Verzenio is currently approved to treat certain HR+, HER2- breast cancers in both early and advanced settings, while the pipeline compounds represent Lilly’s efforts to expand its oncology offerings. Investors can access comprehensive analysis and 14 additional exclusive ProTips for Eli Lilly through InvestingPro, including detailed insights about the company’s upcoming earnings report on October 30, 2025.
In other recent news, Eli Lilly has been the focus of several key developments. Guggenheim raised its price target for Eli Lilly to $948, citing strong sales projections for Mounjaro, with third-quarter sales expected to reach $5.49 billion, slightly above consensus estimates. This follows TD Cowen’s reaffirmation of a Buy rating, maintaining a price target of $960, emphasizing Eli Lilly’s growth prospects and consistent innovation. Additionally, Eli Lilly announced that its ulcerative colitis treatment, Omvoh, demonstrated sustained efficacy over four years, with a significant portion of patients achieving long-term remission. Guggenheim also reiterated a Buy rating with a $875 target, highlighting the company’s anticipated growth and sustainable margins. These developments reflect a positive outlook for Eli Lilly, supported by strong sales forecasts and promising clinical results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.